FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2164995655> ?p ?o ?g. }

• W2164995655 endingPage "3910" @default.
• W2164995655 startingPage "3903" @default.
• W2164995655 abstract "Treatment of secondary CNS dissemination in patients with aggressive lymphomas remains an important, unmet clinical need. Herein, we report the final results of a multicenter phase II trial addressing a new treatment for secondary CNS lymphoma based on encouraging experiences with high doses of antimetabolites in primary CNS lymphoma and with rituximab plus high-dose sequential chemoimmunotherapy (R-HDS) in relapsed aggressive lymphoma.HIV-negative patients with aggressive B-cell lymphoma and secondary CNS involvement at diagnosis or relapse, age 18 to 70 years, and Eastern Cooperative Oncology Group performance status ≤ 3 were enrolled and treated with high-doses of methotrexate and cytarabine, followed by R-HDS (cyclophosphamide, cytarabine, and etoposide) supported by autologous stem-cell transplantation (ASCT). Treatment included eight doses of rituximab and four doses of intrathecal liposomal cytarabine. The primary end point was 2-year event-free survival; the planned accrual was 38 patients.Thirty-eight patients were enrolled; CNS disease was detected at presentation in 16 patients. Toxicity was usually hematologic and manageable, with grade 4 febrile neutropenia in 3% of delivered courses and grade 4 nonhematologic toxicity in 2% of delivered courses. Four patients died because of toxicity. Autologous stem cells were successfully collected in 24 (89%) of 27 patients (median, 10 × 10(6)/kg); 20 patients underwent ASCT. Complete response was achieved in 24 patients (complete response rate, 63%; 95% CI, 48% to 78%). At a median follow-up of 48 months, 17 patients remained relapse free, with a 2-year event-free survival rate of 50% ± 8%. At 5 years, 16 patients were alive, with a 5-year overall survival rate of 41% ± 8% for the whole series and 68% ± 11% for patients who received transplantation. Systemic (extra-CNS) and/or meningeal disease did not affect outcome.The combination of high doses of antimetabolites, R-HDS, and ASCT is feasible and effective in patients age 18 to 70 years old with secondary CNS lymphoma, and we propose it as a new standard therapeutic option." @default.
• W2164995655 created "2016-06-24" @default.
• W2164995655 creator A5003232812 @default.
• W2164995655 creator A5005319283 @default.
• W2164995655 creator A5015825420 @default.
• W2164995655 creator A5025505120 @default.
• W2164995655 creator A5026667594 @default.
• W2164995655 creator A5031300985 @default.
• W2164995655 creator A5031391013 @default.
• W2164995655 creator A5058706557 @default.
• W2164995655 creator A5058765211 @default.
• W2164995655 creator A5062656872 @default.
• W2164995655 creator A5064354905 @default.
• W2164995655 creator A5066814162 @default.
• W2164995655 creator A5068215140 @default.
• W2164995655 creator A5069410590 @default.
• W2164995655 creator A5076571467 @default.
• W2164995655 creator A5085410438 @default.
• W2164995655 creator A5086007176 @default.
• W2164995655 creator A5090199263 @default.
• W2164995655 date "2015-11-20" @default.
• W2164995655 modified "2023-10-17" @default.
• W2164995655 title "High Doses of Antimetabolites Followed by High-Dose Sequential Chemoimmunotherapy and Autologous Stem-Cell Transplantation in Patients With Systemic B-Cell Lymphoma and Secondary CNS Involvement: Final Results of a Multicenter Phase II Trial" @default.
• W2164995655 cites W1608441558 @default.
• W2164995655 cites W173609426 @default.
• W2164995655 cites W1870847635 @default.
• W2164995655 cites W1931431191 @default.
• W2164995655 cites W1966247028 @default.
• W2164995655 cites W1984819380 @default.
• W2164995655 cites W2000339305 @default.
• W2164995655 cites W2018023615 @default.
• W2164995655 cites W2025868687 @default.
• W2164995655 cites W2071364749 @default.
• W2164995655 cites W2097834950 @default.
• W2164995655 cites W2106214522 @default.
• W2164995655 cites W2111322227 @default.
• W2164995655 cites W2133201432 @default.
• W2164995655 cites W2140622698 @default.
• W2164995655 cites W2142991507 @default.
• W2164995655 cites W2150587745 @default.
• W2164995655 cites W2158689824 @default.
• W2164995655 cites W2557250380 @default.
• W2164995655 doi "https://doi.org/10.1200/jco.2015.61.1236" @default.
• W2164995655 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26282634" @default.
• W2164995655 hasPublicationYear "2015" @default.
• W2164995655 type Work @default.
• W2164995655 sameAs 2164995655 @default.
• W2164995655 citedByCount "88" @default.
• W2164995655 countsByYear W21649956552015 @default.
• W2164995655 countsByYear W21649956552016 @default.
• W2164995655 countsByYear W21649956552017 @default.
• W2164995655 countsByYear W21649956552018 @default.
• W2164995655 countsByYear W21649956552019 @default.
• W2164995655 countsByYear W21649956552020 @default.
• W2164995655 countsByYear W21649956552021 @default.
• W2164995655 countsByYear W21649956552022 @default.
• W2164995655 countsByYear W21649956552023 @default.
• W2164995655 crossrefType "journal-article" @default.
• W2164995655 hasAuthorship W2164995655A5003232812 @default.
• W2164995655 hasAuthorship W2164995655A5005319283 @default.
• W2164995655 hasAuthorship W2164995655A5015825420 @default.
• W2164995655 hasAuthorship W2164995655A5025505120 @default.
• W2164995655 hasAuthorship W2164995655A5026667594 @default.
• W2164995655 hasAuthorship W2164995655A5031300985 @default.
• W2164995655 hasAuthorship W2164995655A5031391013 @default.
• W2164995655 hasAuthorship W2164995655A5058706557 @default.
• W2164995655 hasAuthorship W2164995655A5058765211 @default.
• W2164995655 hasAuthorship W2164995655A5062656872 @default.
• W2164995655 hasAuthorship W2164995655A5064354905 @default.
• W2164995655 hasAuthorship W2164995655A5066814162 @default.
• W2164995655 hasAuthorship W2164995655A5068215140 @default.
• W2164995655 hasAuthorship W2164995655A5069410590 @default.
• W2164995655 hasAuthorship W2164995655A5076571467 @default.
• W2164995655 hasAuthorship W2164995655A5085410438 @default.
• W2164995655 hasAuthorship W2164995655A5086007176 @default.
• W2164995655 hasAuthorship W2164995655A5090199263 @default.
• W2164995655 hasBestOaLocation W21649956551 @default.
• W2164995655 hasConcept C126322002 @default.
• W2164995655 hasConcept C141071460 @default.
• W2164995655 hasConcept C143998085 @default.
• W2164995655 hasConcept C203092338 @default.
• W2164995655 hasConcept C2776694085 @default.
• W2164995655 hasConcept C2776755627 @default.
• W2164995655 hasConcept C2777063308 @default.
• W2164995655 hasConcept C2778041864 @default.
• W2164995655 hasConcept C2778119113 @default.
• W2164995655 hasConcept C2778850193 @default.
• W2164995655 hasConcept C2779050716 @default.
• W2164995655 hasConcept C2779338263 @default.
• W2164995655 hasConcept C2780653079 @default.
• W2164995655 hasConcept C2780790343 @default.
• W2164995655 hasConcept C2911091166 @default.
• W2164995655 hasConcept C535046627 @default.
• W2164995655 hasConcept C71924100 @default.
• W2164995655 hasConcept C90924648 @default.
• W2164995655 hasConceptScore W2164995655C126322002 @default.
• W2164995655 hasConceptScore W2164995655C141071460 @default.
• W2164995655 hasConceptScore W2164995655C143998085 @default.

• next